Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2026Expert Opinion on Biological Therapy

An evaluation of axatilimab for the treatment of chronic graft-versus-host disease

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSaurabh ChhabraSBSriram Banigallapati

Discussion

Loading...

Member takes

Overview

Clinical trials evaluate axatilimab’s efficacy and safety in chronic graft-versus-host disease, indicating potential benefits but unanswered questions remain.

Key Points

  • To assess the safety and efficacy of axatilimab for treating chronic graft-versus-host disease (cGVHD).
  • Clinical trials evaluating axatilimab for cGVHD treatment
  • Safety and tolerability assessments
  • Efficacy compared to other treatments
  • Axatilimab shows safety and tolerability in trials
  • Efficacy demonstrated but compared to other therapies remains uncertain
  • Concerns exist regarding long-term safety and combination therapy effects

Cite This Study

Chhabra et al. (2026) studied this question.

synapsesocial.com/papers/69bf8692f665edcd009e8e11https://doi.org/10.1080/14712598.2026.2649515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of response and safety profile of axatilimab in chronic GVHD: Pooled analysis of 384 patients.2026
  2. 2Axatilimab (Niktimvo®) in chronic graft-versus-host disease: a profile of its use2026
  3. 3Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease2025
  4. 4Data from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy2025
  5. 5Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program2025 · 1 citations